ArticleFrontiers in public health2026
Survival outcomes and influencing factors in Zhengzhou HIV/AIDS patients following antiretroviral therapy initiation (2014-2024): a retrospective cohort analysis.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While antiretroviral therapy (ART) has significantly improved the long-term survival of people living with HIV/AIDS, leading to a chronic disease management model, survival outcomes can be influenced by demographic and clinical factors. There is a need to evaluate the long-term survival of HIV-infected individuals initiating ART and identify local influencing factors to optimize patient management and improve prognosis. Methods: A retrospective cohort study was conducted on HIV-infected individuals who initiated ART in Zhengzhou between 2014 and 2024. Demographic data and ART-related information were collected from the National AIDS Clinical Data System. The life table method was employed to describe patient survival time, while the Kaplan-Meier method was used to compare survival time differences under various conditions and to plot survival curves. A Cox proportional hazards regression model was applied to analyze risk factors influencing patient survival time. Results: Among the 3,312 HIV-infected individuals, the total follow-up time amounted to 15,656.5 person-years, with a median follow-up of 4.73 years. A total of 107 deaths were recorded, yielding a mortality rate of 0.68 per 100 person-years. The cumulative survival rates at 1, 3, 5, and 10 years were 99%, 98%, 96%, and 93%, respectively. Multivariate Cox regression analysis identified age greater than 60 years (HR = 5.570, 95% CI: 1.608-19.292) as a risk factor for mortality. Additionally, patients with a baseline CD4 Conclusion: From 2014 to 2024, the overall survival of HIV-infected individuals receiving antiviral therapy in Zhengzhou was favorable. However, advanced age and a low baseline CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.